{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:46:37Z","timestamp":1766407597179,"version":"3.37.3"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Pulmonology"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Methicillin\u2010resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) infections in cystic fibrosis (CF) patients have greatly increased in prevalence in the past two decades and may lead to a more rapid rate of lung function decline. The objective of this study was to determine the impact of a MRSA eradication protocol on long\u2010term culture results and clinical outcomes of pediatric CF patients in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a single\u2010center, retrospective study of children age 30 days to 17 years. Eradication followed the STAR\u2010too study protocol. The primary outcome was the percent of patients with MRSA\u2010negative cultures at 12 months. Secondary outcomes were the percent of patients with negative cultures at 3, 6, and greater than 12 months\u00a0and changes in clinical outcomes compared to individual baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 55 patients who met inclusion criteria, 10 received protocol eradication. Baseline characteristics were similar between eradication and control groups except more eradication patients were on ivacaftor (30% vs 4%; <jats:italic>P<\/jats:italic>\u2009=\u2009.037). Two eradication patients did not receive rifampin due to ivacaftor use. Eradication did not significantly increase the percent of MRSA\u2010negative cultures at 3 months (<jats:italic>P<\/jats:italic>\u2009=\u2009.122), 6 months (<jats:italic>P<\/jats:italic>\u2009=\u2009.058), or 12 months (<jats:italic>P<\/jats:italic>\u2009=\u2009.108); however, did increase culture negativity at greater than 12 months (<jats:italic>P<\/jats:italic>\u2009=\u2009.008). Eradication resulted in no significant differences in clinical outcomes compared to control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>An extensive eradication protocol may lead to an increased clearance rate of long\u2010term CF respiratory cultures but does not appear to affect clinical outcomes. Eradication may be reasonable to attempt; however, more data is needed before routine recommendation in all patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ppul.24628","type":"journal-article","created":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T17:04:25Z","timestamp":1578071065000},"page":"654-659","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of a methicillin\u2010resistant <i>Staphylococcus aureus<\/i> (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients"],"prefix":"10.1002","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7522-1850","authenticated-orcid":false,"given":"Emily","family":"Belarski","sequence":"first","affiliation":[{"name":"Department of Pharmacy University of Chicago Medicine Comer Children's Hospital  Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Pettit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Riley Hospital for Children at Indiana University Health  Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Cystic Fibrosis Foundation Patient Registry.2017Annual Data Reports. Bethesda Maryland."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709010-00001"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200802-327OC"},{"issue":"2","key":"e_1_2_6_5_1","first-page":"97","article-title":"Eradication of methicillin\u2010resistant Staphylococcus aureus from the lower respiratory tract of patients with cystic fibrosis","volume":"6","author":"Burdge DR","year":"1995","journal-title":"Can J Infec Dis"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10231"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2003.12.003"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2006.10.011"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2009.11.009"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00064-2015"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.01.013"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23519"},{"issue":"20","key":"e_1_2_6_13_1","first-page":"1","article-title":"Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short\u2010term local and systematic antibiotic scheme","volume":"18","author":"Kiefer A","year":"2018","journal-title":"BMC Pulm Med"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-208949"},{"key":"e_1_2_6_15_1","unstructured":"The UK Cystic Fibrosis Trust Infection Control Working Group.Methicillin\u2010resistantStaphylococcus aureus(MRSA).2008. London England UK."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/676882"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.07.005"},{"key":"e_1_2_6_18_1","unstructured":"NCT03489629. STaph Aureus Resistance\u2010Treat Early and Repeat (STAR\u2010TER). University of North Carolina Chapel Hill."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"}],"container-title":["Pediatric Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.24628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ppul.24628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ppul.24628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:36:05Z","timestamp":1694158565000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ppul.24628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1002\/ppul.24628"],"URL":"https:\/\/doi.org\/10.1002\/ppul.24628","archive":["Portico"],"relation":{},"ISSN":["8755-6863","1099-0496"],"issn-type":[{"type":"print","value":"8755-6863"},{"type":"electronic","value":"1099-0496"}],"subject":[],"published":{"date-parts":[[2020,1,3]]},"assertion":[{"value":"2019-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}